Aggregated News From Investment Management Regulators

Publication of financial reports: Federal Office of Justice imposes disciplinary fine against Elanix Biotechnologies AG

Report/Flag

Please complete the required fields.



On 13 March 2020, the Federal Office of Justice (Bundesamt für JustizBfJ) imposed a disciplinary fine amounting to 2,500 euros against Elanix Biotechnologies AG.

The disciplinary fine order related to a breach of section 325 of the German Commercial Code (HandelsgesetzbuchHGB) by Elanix Biotechnologies AG. Elanix Biotechnologies AG had failed to submit its accounting documents for the financial year 2018 for the purpose of disclosure to the operator of the German Federal Gazette (Bundesanzeiger) in electronic form within the prescribed period. The legal basis for the sanction is section 335 of the HGB.

The company can lodge a complaint against the disciplinary fine order.

Regulator Information

Recent Articles

SEC Approves Registration of First Security-Based Swap Data Repository; Sets the First Compliance Date for Regulation SBSR

The Securities and Exchange Commission today announced that it has approved the registration of its first security-based swap data repository (SDR).

Regulation for a different world

Speech by our CEO, Nikhil Rathi, delivered at Association of Foreign Banks – CEO Programme 2021 – The UK Regulatory Landscape Post-Brexit and Beyond.  Speaker: Nikhil...

Keynote speech by the Chairman of the FSMA at a high-level conference on sustainability reporting organized by the European Commission

On Wednesday, 6 May 2021, Jean-Paul Servais, Chairman of the FSMA and Vice Chair of IOSCO, gave a speech at a major conference of...

Credit Suisse Bonds / Suisse Capital Wealth Bonds (Clone of FCA authorised firms)

Fraudsters are using the details of firms we authorise to try to convince people that they work for a genuine, authorised firm. Find out...

www.myinvestmentoptions.co.uk

We believe this firm may be providing financial services or products in the UK without our authorisation. Find out why you should be wary...

Get the latest from Regulatory.News in your inbox!

×